Oak Hill Bio raises $32.5M (United States, Jun 2026)
$32.5M
$32.5MGenerated social card
Headline
$32.5M to advance rugonersen into late-stage testing for Angelman - Angelman Syndrome News
About
Oak Hill Bio is a therapeutics company focused on developing treatments for rare diseases. They have secured funding to advance rugonersen, an experimental treatment for Angelman syndrome, into late-stage clinical testing, highlighting their commitment to addressing unmet medical needs in this community.
Article summary
$32.5M to advance rugonersen into late-stage testing for Angelman Angelman Syndrome News
Founder
Josh Distler
CEO
Investors
Related rounds
| Jun 09, 2026 | Standard Bots | $200.0M | — | United States |
| Jun 09, 2026 | City Therapeutics | $99.5M | Series B | United States |
| Jun 09, 2026 | Evotrex | $30.0M | Series A | United States |
| Jun 09, 2026 | Impulse Space | $500.0M | Series D | United States |